These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28342027)

  • 61. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
    Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
    Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.
    Jadvar H
    Cancer Biother Radiopharm; 2020 Sep; 35(7):475-484. PubMed ID: 32202923
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma.
    Rotmensch J; Whitlock JL; Schwartz JL; Hines JJ; Reba RC; Harper PV
    Am J Obstet Gynecol; 1997 Apr; 176(4):833-40; discussion 840-1. PubMed ID: 9125608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Actinium-225 Targeted Agents: Where Are We Now?
    Mourtada F; Tomiyoshi K; Sims-Mourtada J; Mukai-Sasaki Y; Yagihashi T; Namiki Y; Murai T; Yang DJ; Inoue T
    Brachytherapy; 2023; 22(6):697-708. PubMed ID: 37690972
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preclinical targeted alpha therapy for subcutaneous melanoma.
    Allen BJ; Rizvi SM; Tian Z
    Melanoma Res; 2001 Apr; 11(2):175-82. PubMed ID: 11333128
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.
    Macklis RM; Lin JY; Beresford B; Atcher RW; Hines JJ; Humm JL
    Radiat Res; 1992 May; 130(2):220-6. PubMed ID: 1574578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
    Kleynhans J; Ebenhan T; Cleeren F; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1965-1980. PubMed ID: 38676735
    [TBL] [Abstract][Full Text] [Related]  

  • 69.
    Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
    Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.
    Makvandi M; Dupis E; Engle JW; Nortier FM; Fassbender ME; Simon S; Birnbaum ER; Atcher RW; John KD; Rixe O; Norenberg JP
    Target Oncol; 2018 Apr; 13(2):189-203. PubMed ID: 29423595
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tumor therapy with targeted atomic nanogenerators.
    McDevitt MR; Ma D; Lai LT; Simon J; Borchardt P; Frank RK; Wu K; Pellegrini V; Curcio MJ; Miederer M; Bander NH; Scheinberg DA
    Science; 2001 Nov; 294(5546):1537-40. PubMed ID: 11711678
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
    Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
    Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclotron production of Ac-225 for targeted alpha therapy.
    Apostolidis C; Molinet R; McGinley J; Abbas K; Möllenbeck J; Morgenstern A
    Appl Radiat Isot; 2005 Mar; 62(3):383-7. PubMed ID: 15607913
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeted α therapy for cancer: where we are today and where we are heading.
    Melville G
    Future Oncol; 2015 Nov; 11(22):3065-7. PubMed ID: 26436906
    [No Abstract]   [Full Text] [Related]  

  • 75. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
    Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
    Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.
    Wang G; de Kruijff RM; Rol A; Thijssen L; Mendes E; Morgenstern A; Bruchertseifer F; Stuart MC; Wolterbeek HT; Denkova AG
    Appl Radiat Isot; 2014 Feb; 85():45-53. PubMed ID: 24374072
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.
    Sgouros G; Song H
    Cancer Biother Radiopharm; 2008 Feb; 23(1):74-81. PubMed ID: 18298331
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Radiation-based approaches for therapy and palliation of advanced prostate cancer.
    Lewis B; Sartor O
    Curr Opin Urol; 2012 May; 22(3):183-9. PubMed ID: 22453334
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
    Huneke RB; Pippin CG; Squire RA; Brechbiel MW; Gansow OA; Strand M
    Cancer Res; 1992 Oct; 52(20):5818-20. PubMed ID: 1394209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.